Abbott Laboratories (NYSE:ABT) Stock Acquired Rep. Rick Larsen

Representative Rick Larsen (D-Washington) recently bought shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on October 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on October 6th. The trade occurred in the Representative’s “RICHARD R LARSEN IRA” account.

Representative Rick Larsen also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Zoetis (NYSE:ZTS) on 10/6/2025.
• Purchased $1,001 – $15,000 in shares of Walmart (NYSE:WMT) on 10/6/2025.
• Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 10/6/2025.
• Sold $1,001 – $15,000 in shares of Colgate-Palmolive (NYSE:CL) on 10/6/2025.
• Sold $1,001 – $15,000 in shares of Old Dominion Freight Line (NASDAQ:ODFL) on 10/6/2025.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $128.69 on Friday. The stock has a market capitalization of $223.98 billion, a P/E ratio of 16.13, a P/E/G ratio of 2.44 and a beta of 0.69. The firm’s 50-day moving average price is $132.38 and its two-hundred day moving average price is $131.54. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The business had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. During the same period in the prior year, the firm earned $1.21 EPS. The business’s quarterly revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be issued a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

Analysts Set New Price Targets

A number of research firms have issued reports on ABT. Royal Bank Of Canada reiterated an “outperform” rating and issued a $147.00 target price on shares of Abbott Laboratories in a research note on Thursday. Evercore ISI cut their price objective on shares of Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a research report on Wednesday. Morgan Stanley boosted their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Barclays raised their price target on shares of Abbott Laboratories from $159.00 to $162.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Mizuho increased their price objective on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $147.61.

Institutional Trading of Abbott Laboratories

A number of institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC boosted its stake in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Abbott Laboratories by 17.0% in the first quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker’s stock valued at $5,103,000 after buying an additional 5,590 shares during the period. Hemenway Trust Co LLC boosted its stake in Abbott Laboratories by 4.1% during the first quarter. Hemenway Trust Co LLC now owns 372,188 shares of the healthcare product maker’s stock valued at $49,371,000 after buying an additional 14,775 shares in the last quarter. Cushing Capital Partners LLC acquired a new position in Abbott Laboratories during the first quarter worth about $804,000. Finally, Shepherd Financial Partners LLC raised its position in Abbott Laboratories by 4.5% in the first quarter. Shepherd Financial Partners LLC now owns 3,080 shares of the healthcare product maker’s stock worth $408,000 after acquiring an additional 132 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.46% of the company’s stock.

About Representative Larsen

Rick Larsen (Democratic Party) is a member of the U.S. House, representing Washington’s 2nd Congressional District. He assumed office on January 3, 2001. His current term ends on January 3, 2027.

Larsen (Democratic Party) is running for re-election to the U.S. House to represent Washington’s 2nd Congressional District. He declared candidacy for the 2026 election.

Since at least 2011, Larsen has been assigned to the Committee on Armed Services and the Committee on Transportation and Infrastructure.

Larsen’s first position as an elected official was in 1998 as a member of the Snohomish County Council.

Larsen earned his bachelor’s degree from Pacific Lutheran University. After earning his master’s degree in public affairs from the University of Minnesota, Larsen worked as the director of public affairs for the Washington State Dental Association and then as an economic development official with the Port of Everett. He went on to serve on the Snohomish County Council before seeking election to the U.S. House.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.